Sinclair Pharma PLC Hardman Research: Promising start in the US

TIDMSPH

Sinclair Pharma PLC

12 July 2017

Hardman Research: Promising start in the US

Promising start in the US - In 2016 Sinclair was transformed into a streamlined, pure-play aesthetics company with a concentrated, highly competitive, portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive treatments are benefiting from the trend away from intensive plastic surgery and represent a major growth opportunity. Products are sold directly in Europe and Brazil, and via distributors elsewhere globally. In a detailed trading statement, sales progress of products has been compared to the strong in-market demand, which augurs well for the full year. Silhouette InstaLift is continuing to gain sales traction in the US.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/sinclair-pharma-plc-documents/12.07.17-promising-start-in-the-us.pdf

 
 To contact us:          Contacts: 
  Hardman & Co            Dr Martin Hall 
  35 New Broad Street     [e-mail] 
  London                  Dr Dorothea Hill 
  EC2M 1NH                [e-mail] 
  www.hardmanandco.com    Dr Gregoire Pave 
  Follow us on Twitter    [e-mail] 
  @HardmanandCo           Telephone: [phone] 
                          7622 
 

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAOKDDNPBKDAOD

(END) Dow Jones Newswires

July 12, 2017 02:15 ET (06:15 GMT)